Tests an NMDA enhancer drug for major depressive disorder in adults
Tests an NMDA enhancer against sertraline and a placebo in adults with depression.
Plain-language title generated from the registry record
Registry title: NMDA Modulation in Major Depressive Disorder
Key facts
- Where
- Taichung, TaiwanSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT04637620, who can take part
Where in Taiwan
- Department of Psychiatry, China Medical University HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China Medical University Hospital
- Trial code
- NCT04637620
- Record updated
- 23 October 2026
- Original description
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.Read full original descriptionShow less
NMDA Modulation in Major Depressive Disorder
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.
Inclusion: Have a DSM-5 (American Psychiatric Association) diagnosis of MDD; 17-item Hamilton Rating Scale for Depression total score ≥ 18; Free of antidepressant drugs for at least 2 weeks; Agree to participate in the study and provide informed consent.
Exclusion: Initiating or stopping formal psychotherapy within six weeks prior to enrollment; A history of previously received electroconvulsive therapy; Current substance abuse or history of substance dependence in the past 6 months; History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study; Bipolar depression, schizophrenia or other psychotic disorder; Severe cognitive impairment; A history of severe adverse reaction to SSRIs; Moderate-severe suicidal risks; A treatment-resistant history (that is, they have failed to respond to two or more different classes of antidepressants with adequate dosage and treatment duration; Inability to follow protocol.